Fundraising FoxRiverVest Venture Partners — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Board seatJay Schmelter· per SEC Form D
Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCOmega Funds+2 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesAlexandriaARCH Venture PartnersBering Capital+5 more
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsOrbiMedRA CapitalUS Venture PartnersForbion
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.